Compound for the treatment of pemphigus vulgaris
The invention concerns a T-cell based immunotherapy using peptides which are derived from human membrane protein desmoglein. By applying a medical preparation including a peptide or a combination of peptides, a specific immunological tolerance is triggered. Therefore, the clinical signs of pemphigus vulgaris disease improve, because the base for disease is deprived.
Further information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Machine learning algorithm reveals long-theorized glass phase in crystal
Scientists have found evidence of an elusive, glassy phase of matter that emerges when a crystal’s perfect internal pattern is disrupted. X-ray technology and machine learning converge to shed light…
Mapping plant functional diversity from space
HKU ecologists revolutionize ecosystem monitoring with novel field-satellite integration. An international team of researchers, led by Professor Jin WU from the School of Biological Sciences at The University of Hong…
Inverters with constant full load capability
…enable an increase in the performance of electric drives. Overheating components significantly limit the performance of drivetrains in electric vehicles. Inverters in particular are subject to a high thermal load,…